 Adam Dyson on Aug 17th, 2018 // No Comments
Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) â€“ Equities researchers at B. Riley lowered their Q3 2018 earnings estimates for shares of Eiger Biopharmaceuticals in a research note issued to investors on Monday, August 13th. B. Riley analyst M. Kumar now anticipates that the biotechnology company will post earnings per share of ($0.72) for the quarter, down from their previous forecast of ($0.69). B. Riley currently has a "Buy" rating and a $24.00 price objective on the stock. B. Riley also issued estimates for Eiger Biopharmaceuticals' Q4 2018 earnings at ($0.72) EPS, FY2018 earnings at ($2.75) EPS, Q1 2019 earnings at ($0.80) EPS, Q2 2019 earnings at ($0.75) EPS, Q3 2019 earnings at ($0.72) EPS, Q4 2019 earnings at ($0.68) EPS, FY2019 earnings at ($2.73) EPS, FY2020 earnings at ($2.86) EPS, FY2021 earnings at ($2.13) EPS and FY2022 earnings at ($0.86) EPS. Get Eiger Biopharmaceuticals alerts:
Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its earnings results on Friday, August 10th. The biotechnology company reported ($0.82) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.82). EIGR has been the subject of a number of other reports. BTIG Research increased their target price on shares of Eiger Biopharmaceuticals from $23.00 to $39.00 and gave the company a "buy" rating in a research report on Thursday, May 17th. Piper Jaffray Companies increased their target price on shares of Eiger Biopharmaceuticals to $28.00 and gave the company an "overweight" rating in a research report on Friday, May 18th. ValuEngine lowered shares of Eiger Biopharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday. Zacks Investment Research raised shares of Eiger Biopharmaceuticals from a "hold" rating to a "buy" rating and set a $12.00 price objective for the company in a report on Tuesday, May 15th. Finally, Oppenheimer set a $26.00 price objective on shares of Eiger Biopharmaceuticals and gave the company a "buy" rating in a report on Thursday, May 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. Eiger Biopharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $30.75.
Shares of NASDAQ EIGR opened at $11.80 on Wednesday. The stock has a market capitalization of $101.18 million, a PE ratio of -2.43 and a beta of 1.68. The company has a quick ratio of 4.51, a current ratio of 4.51 and a debt-to-equity ratio of 0.81. Eiger Biopharmaceuticals has a 52 week low of $7.46 and a 52 week high of $18.00.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Jennison Associates LLC grew its holdings in shares of Eiger Biopharmaceuticals by 93.3% in the second quarter. Jennison Associates LLC now owns 1,256,501 shares of the biotechnology company's stock valued at $15,329,000 after purchasing an additional 606,361 shares during the period. GMT Capital Corp purchased a new stake in shares of Eiger Biopharmaceuticals in the second quarter valued at about $3,459,000. Renaissance Technologies LLC grew its holdings in shares of Eiger Biopharmaceuticals by 40.4% in the second quarter. Renaissance Technologies LLC now owns 230,229 shares of the biotechnology company's stock valued at $2,809,000 after purchasing an additional 66,200 shares during the period. BlackRock Inc. grew its holdings in shares of Eiger Biopharmaceuticals by 171.0% in the second quarter. BlackRock Inc. now owns 219,278 shares of the biotechnology company's stock valued at $2,675,000 after purchasing an additional 138,366 shares during the period. Finally, Unterberg Capital LLC grew its holdings in shares of Eiger Biopharmaceuticals by 60.0% in the first quarter. Unterberg Capital LLC now owns 80,000 shares of the biotechnology company's stock valued at $788,000 after purchasing an additional 30,000 shares during the period. 71.61% of the stock is owned by hedge funds and other institutional investors.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection